BioPharma Resources

Drug Trial Radar · NCT05855200

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 892 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

892

Planned (sponsor's estimate)

Start

Aug 1, 2023

Primary completion

Mar 19, 2029

Study completion Mar 27, 2031

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
May 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon cancer.

Conditions

  • Colonic Neoplasms
  • Neoplasms, Colon

Interventions

  • DostarlimabBiological

    Dostarlimab will be administered.

  • CAPEOXDrug

    CAPEOX will be administered.

  • FOLFOXDrug

    FOLFOX will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS) Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 5 years

Locations

266 sites in 28 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Tucson, Arizona · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Washington D.C., District of Columbia · Withdrawn

  • GSK Investigational Site

    Deerfield Beach, Florida · Withdrawn

  • GSK Investigational Site

    Fort Lauderdale, Florida · Withdrawn

  • GSK Investigational Site

    Marietta, Georgia · Withdrawn

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Withdrawn

  • GSK Investigational Site

    Naperville, Illinois · Recruiting

  • GSK Investigational Site

    Naperville, Illinois · Recruiting

  • GSK Investigational Site

    Westwood, Kansas · Recruiting

  • GSK Investigational Site

    Lexington, Kentucky · Withdrawn

  • GSK Investigational Site

    Louisville, Kentucky · Withdrawn

  • GSK Investigational Site

    Baton Rouge, Louisiana · Withdrawn

  • GSK Investigational Site

    Bethesda, Maryland · Recruiting

  • GSK Investigational Site

    Ann Arbor, Michigan · Withdrawn

  • GSK Investigational Site

    Detroit, Michigan · Recruiting

  • GSK Investigational Site

    Minneapolis, Minnesota · Recruiting

  • GSK Investigational Site

    Joplin, Missouri · Withdrawn

  • GSK Investigational Site

    St Louis, Missouri · Withdrawn

  • GSK Investigational Site

    St Louis, Missouri · Withdrawn

  • GSK Investigational Site

    Grand Island, Nebraska · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Withdrawn

  • GSK Investigational Site

    Lebanon, New Hampshire · Withdrawn

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    The Bronx, New York · Recruiting

  • GSK Investigational Site

    Durham, North Carolina · Recruiting

  • GSK Investigational Site

    Akron, Ohio · Recruiting

  • GSK Investigational Site

    Cincinnati, Ohio · Recruiting

  • GSK Investigational Site

    Cleveland, Ohio · Withdrawn

  • GSK Investigational Site

    Cleveland, Ohio · Withdrawn

  • GSK Investigational Site

    Cleveland, Ohio · Withdrawn

  • GSK Investigational Site

    Oklahoma City, Oklahoma · Withdrawn

  • GSK Investigational Site

    Oklahoma City, Oklahoma · Withdrawn

Showing 40 of 266 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.